Search research articles
Contact Us
Filters
Showing results (71-80 of 140) with videos related to
Page
of 14
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 29, 2024
Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study
Christian Dagher, Pernille Bjerre Trent, Rofieda Alwaqfi, et al.
Cancer Science
|
May 25, 2022
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775
Kan Yonemori, Mayu Yunokawa, Kimio Ushijima, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 29, 2025
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy
Ramez Eskander, Jung-Yun Lee, Mansoor Mirza, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 2, 2025
Metabolomic signatures of hypocaloric dietary interventions associate with breast cancer risk in the Nurses' Health Study II
Annalise Schweickart, Cheng Peng, Oana Zeleznik, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 15, 2018
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer
Katherine LaVigne, David M Hyman, Qin C Zhou, et al.
The Journal of Clinical Investigation
|
June 20, 2024
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer
Nicolás Gómez-Banoy, Eduardo J Ortiz, Caroline S Jiang, et al.
Advances in Therapy
|
September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Gynecologic Oncology
|
September 5, 2018
Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy
Brooke A Schlappe, Amy L Weaver, Jennifer A Ducie, et al.
Journal of Gynecologic Oncology
|
May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses
Jung-Yun Lee, Ana Oaknin, Luis Manso, et al.
Advances in Therapy
|
March 6, 2025
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 140) with videos related to
Sort By:
Page
of 14
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 29, 2024
Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study
Christian Dagher, Pernille Bjerre Trent, Rofieda Alwaqfi, et al.
Cancer Science
|
May 25, 2022
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775
Kan Yonemori, Mayu Yunokawa, Kimio Ushijima, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 29, 2025
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy
Ramez Eskander, Jung-Yun Lee, Mansoor Mirza, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 2, 2025
Metabolomic signatures of hypocaloric dietary interventions associate with breast cancer risk in the Nurses' Health Study II
Annalise Schweickart, Cheng Peng, Oana Zeleznik, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 15, 2018
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer
Katherine LaVigne, David M Hyman, Qin C Zhou, et al.
The Journal of Clinical Investigation
|
June 20, 2024
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer
Nicolás Gómez-Banoy, Eduardo J Ortiz, Caroline S Jiang, et al.
Advances in Therapy
|
September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Gynecologic Oncology
|
September 5, 2018
Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy
Brooke A Schlappe, Amy L Weaver, Jennifer A Ducie, et al.
Journal of Gynecologic Oncology
|
May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses
Jung-Yun Lee, Ana Oaknin, Luis Manso, et al.
Advances in Therapy
|
March 6, 2025
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Page
of 14